Greenwich Competitors
| GLSI Stock | USD 30.02 1.43 5.00% |
Greenwich Lifesciences vs Immix Biopharma Correlation
Weak diversification
The correlation between Greenwich Lifesciences and IMMX is 0.38 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Greenwich Lifesciences and IMMX in the same portfolio, assuming nothing else is changed.
Moving against Greenwich Stock
| 0.85 | LIXT | Lixte Biotechnology | PairCorr |
| 0.81 | PCSA | Processa Pharmaceuticals | PairCorr |
| 0.79 | CRIS | Curis Inc | PairCorr |
| 0.73 | BCTX | Briacell Therapeutics | PairCorr |
| 0.72 | SYBX | Synlogic | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Greenwich Lifesciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Greenwich Lifesciences Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Greenwich Lifesciences and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Greenwich and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Greenwich Lifesciences does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Greenwich Stock performing well and Greenwich Lifesciences Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Greenwich Lifesciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| CGTX | 3.99 | (0.51) | 0.00 | (0.16) | 0.00 | 8.89 | 24.96 | |||
| ATOS | 3.18 | (0.65) | 0.00 | (0.25) | 0.00 | 6.78 | 20.34 | |||
| TVGN | 4.86 | (1.05) | 0.00 | (0.33) | 0.00 | 10.00 | 26.81 | |||
| ONCY | 3.65 | (0.11) | (0.01) | 0.01 | 4.53 | 8.55 | 27.05 | |||
| SRZN | 4.32 | 0.79 | 0.16 | 0.75 | 4.25 | 13.34 | 34.29 | |||
| HURA | 4.45 | (1.94) | 0.00 | (0.65) | 0.00 | 7.73 | 50.34 | |||
| SEER | 1.46 | (0.27) | 0.00 | (0.29) | 0.00 | 3.41 | 9.98 | |||
| IRD | 3.39 | 0.52 | 0.12 | 1.76 | 3.55 | 7.62 | 26.50 | |||
| AGEN | 3.17 | (0.38) | 0.00 | (0.84) | 0.00 | 6.63 | 30.06 | |||
| IMMX | 5.08 | 1.19 | 0.23 | (24.07) | 4.31 | 15.04 | 28.79 |
Cross Equities Net Income Analysis
Compare Greenwich Lifesciences and related stocks such as Cognition Therapeutics, Atossa Genetics, and Tevogen Bio Holdings Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CGTX | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (10.1 M) | (11.7 M) | 757 K | (25.8 M) | (34 M) | (30.6 M) | (29 M) |
| ATOS | (122.9 K) | (3.4 M) | (5.1 M) | (10.8 M) | (14.7 M) | (15.8 M) | (6.4 M) | (8.1 M) | (11.4 M) | (17.2 M) | (17.8 M) | (20.6 M) | (26.2 M) | (30.1 M) | (25.5 M) | (23 M) | (21.8 M) |
| TVGN | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | 4.4 M | (60.5 M) | (10.1 M) | (9.1 M) | (9.6 M) |
| ONCY | (574.5 K) | (29 M) | (36.4 M) | (23.5 M) | (18.6 M) | (13.7 M) | (15.1 M) | (15.6 M) | (17 M) | (45.6 M) | (16.8 M) | (21 M) | (19.1 M) | (20.6 M) | (31.7 M) | (28.5 M) | (27.1 M) |
| SRZN | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (32.6 M) | (52.5 M) | (27.7 M) | (43 M) | (63.6 M) | (57.2 M) | (60.1 M) |
| HURA | (5.6 K) | (18.9 K) | (8.3 M) | (8.3 M) | (4.3 M) | (8.9 M) | (8.1 M) | (11.1 M) | (8 M) | (9.1 M) | (38.3 M) | (7 M) | (9.4 M) | (29.3 M) | (21.7 M) | (19.5 M) | (18.5 M) |
| SEER | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (16 M) | (32.8 M) | (71.2 M) | (93 M) | (86.3 M) | (86.6 M) | (77.9 M) | (81.8 M) |
| IRD | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (24.6 M) | (56.7 M) | 17.9 M | (10 M) | (57.5 M) | (51.8 M) | (49.2 M) |
| AGEN | (18.1 M) | (23.3 M) | (11.3 M) | (30.1 M) | (42.5 M) | (87.9 M) | (127 M) | (120.7 M) | (159.7 M) | (107.7 M) | (180.9 M) | (23.9 M) | (220.1 M) | (245.8 M) | (227.2 M) | (204.5 M) | (194.3 M) |
| IMMX | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (1.1 M) | (24.4 M) | (8.2 M) | (15.4 M) | (21.6 M) | (19.5 M) | (18.5 M) |
Greenwich Lifesciences and related stocks such as Cognition Therapeutics, Atossa Genetics, and Tevogen Bio Holdings Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Greenwich Lifesciences financial statement analysis. It represents the amount of money remaining after all of Greenwich Lifesciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Greenwich Lifesciences Competitive Analysis
The better you understand Greenwich Lifesciences competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Greenwich Lifesciences' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Greenwich Lifesciences' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Greenwich Lifesciences Competition Performance Charts
Five steps to successful analysis of Greenwich Lifesciences Competition
Greenwich Lifesciences' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Greenwich Lifesciences in relation to its competition. Greenwich Lifesciences' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Greenwich Lifesciences in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Greenwich Lifesciences' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Greenwich Lifesciences, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Greenwich Lifesciences position
In addition to having Greenwich Lifesciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Money Market Funds Thematic Idea Now
Money Market Funds
Funds or Etfs investing in various types of short-term (less than one year) fixed income instruments of high-quality and liquidity. The Money Market Funds theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Money Market Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Greenwich Lifesciences Correlation with its peers. For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is there potential for Biotechnology market expansion? Will Greenwich introduce new products? Factors like these will boost the valuation of Greenwich Lifesciences. Market participants price Greenwich higher when confident in its future expansion prospects. Understanding fair value requires weighing current performance against future potential. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Investors evaluate Greenwich Lifesciences using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Greenwich Lifesciences' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Greenwich Lifesciences' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Greenwich Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Greenwich Lifesciences' market price signifies the transaction level at which participants voluntarily complete trades.